Trial Profile
A Phase IIa Multicenter Trial to Assess the Efficacy, and Safety of Anakinra in Patients With Intravenous Immunoglobulin-resistant Kawasaki Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2022
Price :
$35
*
At a glance
- Drugs Anakinra (Primary)
- Indications Mucocutaneous lymph node syndrome
- Focus Proof of concept; Therapeutic Use
- Acronyms KAWAKINRA
- 11 Aug 2020 Results published in the Arthritis and Rheumatology
- 01 Jul 2019 Status changed from active, no longer recruiting to completed.
- 15 Jun 2019 Status changed to active, no longer recruiting as per results presented at the 20th Annual Congress of the European League Against Rheumatism